此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers

2026年6月10日 更新者:Valenta Pharm JSC

An Open-Label Study to Evaluate the Effect of Food on the Bioavailability of 4-MUST, 128 mg, Tablets and to Assess the Pharmacokinetics, Safety, and Tolerability Following Single and Multiple Dose Administration in Healthy Volunteers

This open-label study will evaluate the effect of food on the bioavailability of a single dose of 4-MUST, tablets, 128 mg. Additionally, the study will assess the pharmacokinetics, safety, and tolerability of 4-MUST, tablets, 128 mg following both single and multiple oral dose administration.

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

45

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Moscow、俄罗斯、119991
        • 招聘中
        • I.M. Sechenov First Moscow State Medical University
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Voluntary, personally signed ICF obtained prior to any study procedures;
  • Males and females aged 18 to 45 years (inclusive) of Caucasian race;
  • Confirmed healthy status based on the absence of clinically significant abnormalities in clinical, laboratory, and diagnostic assessments specified in the protocol;
  • Blood pressure (BP): systolic blood pressure (SBP) from 99 to 129 mmHg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mmHg (inclusive);
  • Heart rate (HR) from 60 to 89 beats/min (inclusive);
  • Respiratory rate (RR) from 12 to 20 per 1 minute (inclusive);
  • Body temperature from 36.0°C to 36.9°C (inclusive);
  • Body mass index (BMI) of 18.5 kg/m2 ≤ BMI ≤ 30 kg/m2, with body weight ≥ 55 kg for males and ≥ 45 kg for females;
  • Commitment to adhere to highly effective contraceptive methods during the study participation period and for 30 days thereafter; documentation of negative urine pregnancy test for women of childbearing potential.

Noninclusion Criteria:

  • History of clinically significant allergic reactions;
  • Hypersensitivity to hymecromone and trimebutine and/or excipients included in the study drug in anamnesis;
  • Drug intolerance to hymecromone and trimebutine and/or excipients included in the study drug in the anamnesis;
  • Hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption in the anamnesis;
  • Chronic diseases of the kidney, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, genitourinary and immune systems, as well as skin, hematopoietic and visual organs;
  • History of GI surgery (except for appendectomy at least 1 year prior to screening);
  • Diseases/conditions that, in the opinion of the investigator, may affect the absorption, distribution, metabolism, or excretion of the study drug;
  • Acute infectious diseases less than 4 weeks prior to screening;
  • Intake of drugs that have a significant effect on hemodynamics and drugs that affect liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before screening;
  • Regular intake of a medicine less than 2 weeks prior to screening and single intake of a medicine less than 7 days prior to screening (including over-the-counter medicines, vitamins, supplements, herbs);
  • Blood or plasma donation less than 3 months prior to screening;
  • Use of hormonal contraceptives (in women) less than 2 months prior to screening;
  • Use of depot injections of any medicine less than 3 months prior to screening;
  • Pregnancy or lactation period; positive pregnancy test for women of childbearing potential;
  • Women of childbearing potential who have had unprotected sexual intercourse with a non-sterilized male partner within 30 days prior to administration of the study drug;
  • Participation in another clinical trial less than 3 months prior to screening or concurrent with the present study;
  • Consumption of more than 10 units of alcohol per week during the month prior to study enrollment (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine, or 50 mL of spirits), or a history of alcoholism, drug dependence, or abuse of medicinal products;
  • Smoking more than 10 cigarettes per day currently, or a history of smoking the indicated number of cigarettes in the 6 months preceding screening; failure to agree to abstain from smoking for the duration of the hospital stay;
  • Consumption of alcohol, caffeine, and xanthine-containing products in the 7 days prior to taking the study drug;
  • Consumption of citrus fruits, cranberries, rose hips and products containing them, preparations or products containing St. John's wort - 7 days before taking the study drug;
  • Dehydration due to diarrhea, vomiting, or other cause within the last 24 hours prior to taking the study drug;
  • Positive blood test result for antibodies to human immunodeficiency virus (HIV) 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens at screening;
  • Clinically significant abnormalities on electrocardiogram (ECG) in the medical history and/or at screening;
  • Positive urinalysis for narcotics and potent drugs at screening;
  • Positive breath alcohol vapor test at screening;
  • Scheduling a hospital stay during the study period, for any reason other than hospitalization required by this protocol;
  • Failure or inability to comply with protocol requirements, follow protocol procedures, diet and activity regimen.
  • Belonging to a vulnerable population, including: students enrolled in medical, pharmaceutical, or dental educational institutions, clinical and laboratory assistants, pharmaceutical company employees, military personnel and prisoners, persons residing in residential care facilities, low-income and unemployed, minorities, homeless, vagrants, refugees, persons in foster care, persons unable to consent, and law enforcement officers;
  • Any other condition that, in the judgement of the Investigator, would preclude the volunteer's enrollment in the study or could lead to premature withdrawal from the study, including adherence to fasting regimens or special diets (e.g., vegetarian, vegan, or sodium-restricted diets) or lifestyle factors (e.g., night-shift work or extreme physical exertion)

Exclusion criteria:

  • Voluntary withdrawal of the subject from the study;
  • Failure to comply with protocol requirements by the volunteer (e.g., missing scheduled study procedures, unauthorized use of prohibited medications, or violation of dietary or lifestyle restrictions);
  • Occurrence of any event or condition during the study that, in the investigator's judgement, may compromise the volunteer's safety (e.g., hypersensitivity reactions);
  • Volunteers selected for participation in the study in violation of the inclusion/non-inclusion criteria;
  • Development of severe adverse event and/or a serious adverse event in a volunteer during the course of the study;
  • Volunteer is receiving or requires treatment that may affect the pharmacokinetic parameters of the study drug;
  • Missing collection of 2 or more consecutive blood samples or 3 x or more blood samples during the same Study Period;
  • Occurrence of vomiting/diarrhea within 6 h after administration of study drug;
  • Positive urine test for narcotics and potent drugs;
  • Positive breath alcohol test;
  • Positive pregnancy test in women;
  • Occurrence of any other circumstance that precludes conduct of the study in accordance with the protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:AB sequence
Cohort 1, Group 1 (sequence AB) will receive 3 tablets (384 mg) of the study drug under fasting conditions in Period I and under fed conditions in Period II.
128 mg tablets containing trimebutine 4-methylumbelliferyl sulfate (4-MUST)
其他名称:
  • Trimebutine 4-甲基固体硫酸盐
实验性的:BA sequence
Cohort 1, Group 2 (sequence AB)will receive 3 tablets (384 mg) of the study drug under fed conditions in Period I and under fasting conditions in Period II.
128 mg tablets containing trimebutine 4-methylumbelliferyl sulfate (4-MUST)
其他名称:
  • Trimebutine 4-甲基固体硫酸盐
实验性的:Multiple dosing
Cohort 2, Multiple dose: 3 tablets (384 mg) three times daily, 30 minutes before meals, for 3 consecutive days (with the last dose taken in the morning of Day 4).
128 mg tablets containing trimebutine 4-methylumbelliferyl sulfate (4-MUST)
其他名称:
  • Trimebutine 4-甲基固体硫酸盐

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
药代动力学 - AUC 比率
大体时间:0 至 48 小时(第 1-3 天和第 8-10 天)
观察时间内浓度-时间曲线下面积与计算的浓度-时间曲线下从零到无穷大面积的比值
0 至 48 小时(第 1-3 天和第 8-10 天)
药代动力学 - Cmax/AUC0-t
大体时间:0 至 48 小时(第 1-3 天和第 8-10 天)
观察期间最大浓度与浓度-时间曲线下面积之比
0 至 48 小时(第 1-3 天和第 8-10 天)
药代动力学 - f'
大体时间:0 至 48 小时(第 1-3 天和第 8-10 天)
f' - 相对生物利用度(AUC(0-t)(进食)/AUC(0-t)(空腹))
0 至 48 小时(第 1-3 天和第 8-10 天)
药代动力学 - f''
大体时间:0 至 48 小时(第 1-3 天和第 8-10 天)
f'' 是相对吸收率(Cmax(进食)/Cmax(空腹))
0 至 48 小时(第 1-3 天和第 8-10 天)
Pharmacokinetics - Cmax
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Maximum plasma concentration (Cmax) of 4-MUST metabolites: trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - tmax
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Time to reach Cmax (tmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - AUC0-t
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - AUC0-inf
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - t1/2
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Elimination half-life (t1/2) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - kel
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Elimination constant (kel) of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - MRT
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Mean residence time (MRT) of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics - Vd
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Volume of distribution of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 48 hours (days 1-3 and 8-10)
Bioavailability - ratio of Cmax
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Ratio of geometric mean Cmax for trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)
From 0 to 48 hours (days 1-3 and 8-10)
Bioavailability - ratio of AUC0-t
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Ratio of geometric mean AUC0-t for of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)
From 0 to 48 hours (days 1-3 and 8-10)
Bioavailability - ratio of AUC0-inf
大体时间:From 0 to 48 hours (days 1-3 and 8-10)
Ratio of geometric mean AUC0-inf for of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide under fasted and fed conditions (with 90% confidence intervals)
From 0 to 48 hours (days 1-3 and 8-10)
Pharmacokinetics (multiple dosing) - number of terminal timepoints
大体时间:From 72 to 120 hours
number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant of of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - Cmax
大体时间:From 72 to 120 hours
Maximum plasma concentration (Cmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - tmax
大体时间:From 72 to 120 hours
Time to reach Cmax (tmax) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - AUC0-t
大体时间:From 72 to 120 hours
Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - AUC0-inf
大体时间:From 72 to 120 hours
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - AUCextr
大体时间:From 72 to 120 hours
Extrapolated AUC of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - t1/2
大体时间:From 72 to 120 hours
Elimination half-life (t1/2) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - kel
大体时间:From 72 to 120 hours
Elimination constant (kel) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - MRT
大体时间:From 72 to 120 hours
Mean residence time (MRT) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - Vd
大体时间:From 72 to 120 hours
Volume of distribution of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - CL
大体时间:From 72 to 120 hours
Clearance (CL) of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 72 to 120 hours
Pharmacokinetics (multiple dosing) - Cmax,ss
大体时间:From 0 to 72 hours
Maximum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 72 hours
Pharmacokinetics (multiple dosing) - tmax,ss
大体时间:From 0 to 72 hours
Time to reach maximum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 72 hours
Pharmacokinetics (multiple dosing) - tmin,ss
大体时间:From 0 to 72 hours
Time to reach minimum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 72 hours
Pharmacokinetics (multiple dosing) - Cmin,ss
大体时间:From 0 to 72 hours
Minimum plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 72 hours
Pharmacokinetics (multiple dosing) - Cavg,ss
大体时间:From 0 to 72 hours
Average plasma concentration at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 72 hours
Pharmacokinetics (multiple dosing) - CL,ss
大体时间:From 0 to 72 hours
Clearance at steady state of trimebutine, N-desmethyltrimebutine, 3,4,5-trimethoxybenzoic acid, 4-methylumbelliferone sulfate, 4-methylumbelliferone and 4-methylumbelliferone glucuronide
From 0 to 72 hours

次要结果测量

结果测量
措施说明
大体时间
不良事件类型
大体时间:从第-14天 - 第-1天(筛选)到第16±1天(研究结束)
通过投诉、体格检查结果、心率和血压评估结果、呼吸频率评估结果、体温、实验室监测(临床血细胞计数、生化血细胞计数、尿液分析)、心电图来评估不良事件;不良事件将根据 MedDRA 进行分类。
从第-14天 - 第-1天(筛选)到第16±1天(研究结束)
不良事件频率
大体时间:从第-14天 - 第-1天(筛选)到第16±1天(研究结束)
研究期间记录的不良事件的数量和频率
从第-14天 - 第-1天(筛选)到第16±1天(研究结束)
与不良事件相关的辍学
大体时间:从第-14天 - 第-1天(筛选)到第16±1天(研究结束)
由于与研究药物相关的不良事件和/或严重不良事件的发生而提前终止参与研究的病例数
从第-14天 - 第-1天(筛选)到第16±1天(研究结束)
Physical examination results - cardiovascular system
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - respiratory system
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - digestive tract
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - endocrine system
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - musculoskeletal system
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the musculoskeletal system on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - nervous system
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - sensory systems
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the sensory systems on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - skin/visible mucous membranes
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Physical examination results - genitourinary system
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
An assessment of the condition of the genitourinary system on physical examination (normal condition or list of abnormal conditions, if any)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - systolic blood pressure
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Systolic blood pressure (SBP, mmHg)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - diastolic blood pressure
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Diastolic blood pressure (DBP, mmHg)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - heart rate
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Heart rate (HR, bpm)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - respiratory rate
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Respiratory rate (breaths per minute)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: vital signs - body temperature (Celsius temperature scale)
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Body temperature (Celsius temperature scale)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6): heart rate (beats per minute)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6): PQ interval (is the period, measured in milliseconds, that extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QRS complex (the QRS complex is the combination of three of the graphical deflections seen on a typical electrocardiogram)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QT interval
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
12-lead ECG (I, II, III, aVR-enhanced unipolar abduction from the right arm , aVL-enhanced unipolar abduction from the left arm, aVF - enhanced unipolar abduction from the left leg, V1-V6) taken while lying down: QT interval (distance from the beginning of the QRS complex to the end of the T wave)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - hemoglobin
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Hemoglobin (g/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - hematocrit
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Hematocrit (%)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - red blood cell count
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Red blood cell count (cells/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - platelet count
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Platelet count (cells/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - leukocyte count
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte count (cells/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Erythrocyte sedimentation rate (mm/h)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - myelocytes
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (myelocytes, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - band neutrophils
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (band neutrophils, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - segmented neutrophils
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (segmented neutrophils, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - eosinophils
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (eosinophils, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - basophils
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (basophils, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - monocytes
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (monocytes, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: clinical blood test - lymphocytes
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Leukocyte formula (lymphocytes, %)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - glucose
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Glucose concentration (mmol/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - cholesterol
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Total cholesterol concentration (mmol/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - total protein
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Total protein in blood serum (g/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - bilirubin
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Total bilirubin concentration (micromol/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - creatinine
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Creatinine concentration (micromol/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - alkaline phosphatase
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Alkaline phosphatase activity (U/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - alanine transaminase
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Alanine transaminase activity (U/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: blood chemistry - aspartate transaminase
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Aspartate transaminase activity (U/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - specific gravity
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Specific gravity of the urine
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - color
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Color of the urine
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - transparency
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Transparency of the urine
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - pH
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
pH of the urine
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - protein
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Protein concentration (g/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - glucose
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Glucose concentration (mmol/L)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - red blood cells
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Red blood cell content (number in sight)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - white blood cells
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
White blood cell content (number in sight)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - casts
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Presence of casts (Yes/No)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - mucus
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Presence of mucus (Yes/No)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Safety and Tolerability: urinalysis - bacteria
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Presence of bacteria (Yes/No)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Adverse event severety
大体时间:From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)
Severity of adverse events registered during the study, assessed using the Common Terminology Criteria for Adverse Events (CTCAE)
From day -14 - day -1 (screening) to day 16 ± 1 (end of the study)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月26日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2026年5月12日

首先提交符合 QC 标准的

2026年5月12日

首次发布 (实际的)

2026年5月19日

研究记录更新

最后更新发布 (实际的)

2026年6月15日

上次提交的符合 QC 标准的更新

2026年6月10日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • GIB-01-05-2025

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅